妨碍仿制药上市最臭名昭著的绊脚石是“付费推迟”协议。根据这项协议，专利持有人可以买通仿制药制造商以推迟其将廉价的复制产品推向市场。
The most egregious offence is the “pay-for-delay” deal, under which a patent-holder pays a maker of generic drugs to delay its launch of a cheap copy.
妨碍仿制药上市最臭名昭著的绊脚石是“付费推迟”协议。根据这项协议，专利持有人可以买通仿制药制造商以推迟其将廉价的复制产品推向市场。
The most egregious offence is the “pay-for-delay” deal, under which a patent-holder pays a maker of generic drugs to delay its launch of a cheap copy.
应用推荐